Bristow Group Inc (BRS) Drops 5.14% on February 19

Equities Staff |

Bristow Group Inc (BRS) was one of the Russell 2000's biggest losers for Friday February 19 as the stock slid 5.14% to $14.03, a loss of $-0.76 per share. Starting at an opening price of $14.65 a share, the stock traded between $13.71 and $14.75 over the course of the trading day. Volume was 490,087 shares over 3,642 trades, against an average daily volume of 806,792 shares and a total float of 34.95 million.

The losses send Bristow Group Inc down to a market cap of $490.37 million. In the last year, Bristow Group Inc has traded between $64.64 and $11.02, and its 50-day SMA is currently $21.59 and 200-day SMA is $36.53.

Bristow Group Inc is a provider of helicopter services to the offshore energy industry based on the number of aircraft operated and one of two helicopter service providers to the offshore energy industry with global operations.

Bristow Group Inc is based out of Houston, TX and has some 5,232 employees. Its CEO is Jonathan E. Baliff.

For a complete fundamental analysis analysis of Bristow Group Inc, check out Equities.com’s Stock Valuation Analysis report for BRS. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Snapchat

Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…